Canagliflozin treatment for 6 months significantly decreased epicardial adipose tissue thickness from 9.3 mm to 7.3 mm in patients with type 2 diabetes mellitus.
Observational (n=13)
Open-label
No
Does canagliflozin reduce epicardial adipose tissue thickness in patients with type 2 diabetes mellitus?
Canagliflozin significantly reduced epicardial adipose tissue thickness in patients with type 2 diabetes mellitus, suggesting a potential mechanism for cardiovascular risk reduction independent of glycemic control.
Absolute Event Rate: 7.3% vs 9.3%
p-value: p=<0.001
BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. CONCLUSION: Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).
Yagi et al. (Wed,) conducted a observational in Type 2 diabetes mellitus (n=13). Canagliflozin vs. Baseline was evaluated on Epicardial adipose tissue (EAT) thickness at 6 months (p=<0.001). Canagliflozin treatment for 6 months significantly decreased epicardial adipose tissue thickness from 9.3 mm to 7.3 mm in patients with type 2 diabetes mellitus.